Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to $44.2 million.

  • GeneDx Holdings' Cash from Financing Activities fell 22.91% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.9 million, marking a year-over-year decrease of 7.28%. This contributed to the annual value of $44.2 million for FY2024, which is 76.29% down from last year.
  • Per GeneDx Holdings' latest filing, its Cash from Financing Activities stood at $44.2 million for FY2024, which was down 76.29% from $186.2 million recorded in FY2023.
  • GeneDx Holdings' 5-year Cash from Financing Activities high stood at $493.7 million for FY2021, and its period low was $44.2 million during FY2024.
  • Its 3-year average for Cash from Financing Activities is $142.6 million, with a median of $186.2 million in 2023.
  • Per our database at Business Quant, GeneDx Holdings' Cash from Financing Activities soared by 282.57% in 2021 and then tumbled by 76.29% in 2024.
  • Yearly analysis of 5 years shows GeneDx Holdings' Cash from Financing Activities stood at $129.1 million in 2020, then spiked by 282.57% to $493.7 million in 2021, then crashed by 60.04% to $197.3 million in 2022, then decreased by 5.61% to $186.2 million in 2023, then slumped by 76.29% to $44.2 million in 2024.